Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia
October 2022
in “
The Journal of Clinical Pharmacology
”
TLDR Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
The study investigated the cardiometabolic effects of bromocriptine in men with prolactin excess, comparing those with early-onset androgenic alopecia (group 1) to those with normal hair growth (group 2). Over 4 months, both groups received 7.5 mg of bromocriptine daily. While bromocriptine reduced prolactin and improved several cardiometabolic markers in both groups, the effects were more pronounced in group 2. Specifically, only group 2 saw increases in HDL cholesterol and decreases in triglycerides, fibrinogen, and UACR. The findings suggest that men with early-onset androgenic alopecia exhibit partial resistance to the cardiometabolic benefits of bromocriptine.